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Abstract
Animal models that represent human diseases constitute an important tool in understanding the
pathogenesis of the diseases, and in developing effective therapies. Neurodegenerative diseases are
complex disorders involving neuropathologic and psychiatric alterations. Although transgenic and
knock-in mouse models of Alzheimer's disease, (AD), Parkinson's disease (PD) and Huntington's
disease (HD) have been created, limited representation in clinical aspects has been recognized and
the rodent models lack true neurodegeneration. Chemical induction of HD and PD in nonhuman
primates (NHP) has been reported, however, the role of intrinsic genetic factors in the
development of the diseases is indeterminable. Nonhuman primates closely parallel humans with
regard to genetic, neuroanatomic, and cognitive/behavioral characteristics. Accordingly, the
development of NHP models for neurodegenerative diseases holds greater promise for success in
the discovery of diagnoses, treatments, and cures than approaches using other animal species.
Therefore, a transgenic NHP carrying a mutant gene similar to that of patients will help to clarify
our understanding of disease onset and progression. Additionally, monitoring disease onset and
development in the transgenic NHP by high resolution brain imaging technology such as MRI, and
behavioral and cognitive testing can all be carried out simultaneously in the NHP but not in other
animal models. Moreover, because of the similarity in motor repertoire between NHPs and
humans, it will also be possible to compare the neurologic syndrome observed in the NHP model
to that in patients. Understanding the correlation between genetic defects and physiologic changes
(e.g. oxidative damage) will lead to a better understanding of disease progression and the
development of patient treatments, medications and preventive approaches for high risk
individuals. The impact of the transgenic NHP model in understanding the role which genetic
disorders play in the development of efficacious interventions and medications is foreseeable.
Background
Transgenic technology in biomedicine has opened a new
era for animal modeling, which accelerates model devel-
opment and results in better understanding of diseases as
well as development of therapies for patients. The success-
ful development of transgenic animal models for human
diseases has led to remarkable breakthroughs that have
significantly impacted the development of approaches to
the diagnosis, treatment, and intervention of human dis-
eases. Additionally, the models have clarified our under-
standing of disease mechanisms and the onset and course
of pathology associated with disease [1-4]. For several rea-
sons, the transgenic mouse is the most commonly used
animal model: the availability of extensive information
for particular strains, well developed techniques in han-
dling gametes, embryos and surrogates; inexpensive and
relatively limitless supplies, and short generation times
[5]. Undeniably, the use of transgenic mice plays a very
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important role in biomedical advancements and this role
will continue to be critical. Transgenic rodents, developed
with genetic defects similar to those seen in human
patients, are widely used in biomedical research. Never-
theless, fundamental differences between rodents and
humans limit the rodent from being the best model for all
human diseases. These physiologic differences include life
span [6], brain complexity [7-11], cellular metabolism
[12], endocrine and reproductive function [13]. The dif-
ferences may be caused by genetic redundancy or altered
biochemical pathways in mice [14,15]. Additionally, lim-
ited cognitive and behavioral tests are available for
rodents, and these are not always applicable to studying
neurodegenerative diseases such as AD, PD and HD.
Therefore, due to the high number of physiologic [16],
neurologic and genetic similarities [17-19] between
humans and NHPs, the latter is considered one of the best
models for understanding human physiology and dis-
eases. Due to progressive neurodegeneration, deleterious
alterations in behavior, and psychiatric status associated
with neurodegenerative diseases such as AD, PD and HD
in humans, the NHP is the only animal model providing
accessibility to a wide range of testing methods and the
possibility for high resolution brain imaging such as func-
tional magnetic resonance imaging (fMRI). The creation
of a transgenic NHP with genetic alteration that leads to
human genetic diseases will further mimic patient condi-
tions with impacts on understanding disease develop-
ment, thereby paving the way for the development of
cures [6,7,20-24].
Major difficulties in generating genetically 
modified NHP
The major difficulty in producing transgenic NHPs is low
efficiency of the gene transfer method. Although the first
transgenic mouse was born in 1974 by infection of a pre-
implantation stage embryo using a competent retrovirus
[25,26], the technique was not widely accepted due to
biosafety concerns, suppression of transgene expression
and high mosaicism rate [27-30]. On the other hand, pro-
nuclear microinjection (PI) has dominated the transgenic
field for more than two decades despite its relatively low
efficiency [30-34], because there were no more efficient
method. Despite concerted efforts to develop a new gene
transfer method and techniques that could improve gene
transfer efficiency [30,33,35], significant improvement
has only been achieved recently. The development of rep-
lication defective retroviral and lentiviral vector systems
[36-44], sperm mediated gene transfer (SMGT) [45-48],
nuclear transplantation technology [49-53], and reliable
transgenic reporters [54-57] have led transgenesis and ani-
mal biotechnology to a new era in which broad applica-
tions can now be achieved.
An efficient gene delivery method is the crucial factor in
transgenic NHP production because, due to ethical con-
cerns, the small number of available animals is the major
limiting factor in the development process. We have
developed the first transgenic NHP, named "ANDi", by
using a pseudotyped retroviral vector as a vehicle to
deliver the gene of interest into an unfertilized oocyte at a
relatively high rate of efficiency [22]. Indeed, the same
method was first proven to be highly efficient in cattle
before it was applied in NHPs [58]. Furthermore, rapid
development of lentiviral vector technology has signifi-
cantly impacted transgenic technology. A comparison of
the two viral vector systems will be discussed in the fol-
lowing section.
Alternative strategies for generating transgenic 
NHP for biomedical research
A number of gene transfer methods has been described for
the production of such transgenic animals such as
rodents, livestock, primates and other species
[22,44,45,58,59]; however, until recently no efficient and
reliable method had been developed for producing the
NHP. Vesicular stomatitis virus envelope glycoprotein G
(VSV-G) pseudotyped retroviral vector (RV-pseudotype) is
an efficient gene delivery system in tissue culture cells,
embryonic stem (ES) cells, gametes and early preimplan-
tation embryos. Transgenic pigs, cattle and NHPs have
also been successfully produced by infecting unfertilized
oocytes [22,58,60]. The unfertilized oocyte was targeted
because of the disassembly of the nuclear membrane at
metaphase; thus it became accessible for the viral preinte-
gration complex to achieve integration. Compared to the
RV, lentiviral vector (LV) capable of infecting both mitotic
and non-mitotic cells, has led to optimism in transgenic
and gene therapeutic technology, although with limita-
tions. Three promising methods of creating genetically
modified NHP models for biomedical research are retro-
viral vector, lentiviral vector, and cloning. One of the
major differences between viral vector gene transfer and
cloning is the transgene integration pattern in the result-
ing animals. Although high gene transfer efficiency has
been demonstrated in RV and LV, site specific integration
is not feasible; however, animal cloning using gene tar-
geted donor cells has been proven as a feasible strategy.
Thus, the method for creating transgenic animals should
be carefully chosen dependent on the requirements of the
animal models and limitations of available technology.
Retroviral vector vs lentiviral vector
Retrovirus and lentivirus belong to the Retroviridae
viruses, which are double stranded (ds) RNA enveloped.
The viral core is comprised of the dsRNA genome and
enzymes such as reverse transcriptase for reverse transcrip-
tion of the RNA genome to DNA followed by integration
achieved by integrase [61]. Both vectors have beenReproductive Biology and Endocrinology 2004, 2 http://www.rbej.com/content/2/1/39
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successfully used to generate transgenic animals at a rela-
tively high rate [22,44,58,60]. Transgenic pigs, cattle and
NHPs have been produced by infecting unfertilized
oocytes using an RV-pseudotype followed by in vitro ferti-
lization, whereas transgenic mice and rats have been pro-
duced by infecting fertilized oocytes (zygotes) using the
LV-pseudotype (Chan unpublished) [44]. Nevertheless,
the capability of infecting non-mitotic cells has been over-
whelmed by the potential application of LV in gene ther-
apy, particularly for patients suffering from
neurodegenerative diseases. Neurons are primarily non
proliferative or at a low mitotic rate, which makes LV a
superior delivery system over other gene transfer methods
including RV. Thus, the LV is undeniably outstanding in
gene therapy for neurologic disorders; however, whether
LV is superior over RV in the production of transgenic ani-
mals such as the NHP remains unknown, and further
investigation is necessary.
To date, the only successful method of producing trans-
genic NHPs is the infection of metaphase II (MII) oocytes
using an RV-pseudotype [22]. Except for NT, all other gene
transfer methods result in random integration of the
transgene. Due to the presence of the endogenous
homolog in the target cell genome, a recessive gene defect
that requires mutation at both alleles will not be achieved
by present gene transfer techniques. Therefore, it is neces-
sary to develop a transgenic NHP model for disease
caused by a single dominant gene disorder that would
result from the gain of function of the mutant gene. Some
inherited genetic disorders resulting from a single domi-
nant gene defect make them good candidates for the crea-
tion of a transgenic NHP model (Table 1). A single
dominant gene disorder has additional advantages over
complex gene disorders. Complex diseases, often resulting
in multiple gene defects, require long selection and breed-
ing programs to establish animal colonies with stable gen-
otypes and phenotypes for further study. Thus, due to the
lengthy breeding time and limitation in present genetic
manipulation techniques, an NHP with a long gestation
period requiring years to reach reproductive age is not
appropriate for complex genetic disorders.
Undoubtedly the crucial role of LV in gene therapy devel-
opment, particularly relating to neurodegenerative dis-
eases, has held great promise. However, it is still unknown
whether LV is more advantageous than RV in the creation
of transgenic animal models such as NHP. The major dif-
ference between LV and RV is the target cell. LV is capable
of infecting the non-mitotic cell, whereas RV infects
mitotic cells only because the presence of the nuclear
envelope in non-mitotic cells precludes entry of the pre-
integration complex into the nucleus followed by integra-
tion. Transgenic rats and mice have been generated by
infecting zygotes using LV. Because LV is capable of infect-
ing target cells at any stage, continuous infection during
early embryonic development and a high mosaicism rate
is expected. On the other hand, RV infecting primarily
mitotic cells is more efficient when targeting MII oocytes
than zygotes. A 100% transgenic rate was achieved when
targeting MII oocytes compared to 25% when targeting
zygotes [58]. This suggests the importance of infection
time and its profound influence on the transgene integra-
tion pattern in the resulting animals. Nonetheless, the
efficiency of generating transgenic animals by RV and LV-
pseudotypes is relatively low compared to pronuclear
microinjection. Thus, further investigation is necessary to
determine the gene transfer efficiency, integration and
expression pattern when a sufficient number of transgenic
animals is available.
Table 1: Autosomal dominant neurodegenerative diseases [97-98]
Disease Mutant Gene Mutation Transgenic Mouse Model
FAD APP Mainly missense Mutant APP and APP:PS1
FAD PS1 Mainly missense Mutant PS1
FAD PS2 Mainly missense Mutant PS2
FALS SOD1 Mainly missense Mutant SOD1
FTDP-17 Tau Missense & splice Mutant Tau
PD α-synuclein Missense wt/mutant αsyn
Prion PrP Mainly missense Mutant PrP
HD huntingtin Polyglutamine huntingtin (expanded repeat)
SCA-1 ataxin-1 Polyglutamine ataxin-1 (expanded repeat)
SCA-3 ataxin-3 Polyglutamine ataxin-3 (expanded repeat)
DRPLA atrophin-1 Polyglutamine atrophin-1 (expanded repeat)
FAD: Familial Alzheimer's Disease FALS: Familial amyotrophic lateral sclerosis with Parkinsonism HD: Huntington's Disease DRPLA: Dentatorubral 
and pallidoluysian atrophy PD: Parkinson's Disease SCA: Spinocerebellar ataxias FTDP: Frontotemporal DementiaReproductive Biology and Endocrinology 2004, 2 http://www.rbej.com/content/2/1/39
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Cloning and ES cell
During the past few years, research in ES cells and cloning
has flourished. Since the establishment of embryonic cell
lines from mouse preimplantation embryos in 1981, the
continuous effort to create identical transgenic animals
using ES cells, embryonic cells and somatic cells by
nuclear transfer finally has been rewarded. ES cell lines
from NHP and human preimplantation embryos have
been established [62-66].
Pluripotency of NHP and human ES cells has also been
demonstrated by the derivation of cell types from various
lineages including neurons, islet cells and cardiac muscle
cells [6,64,65,67]. However, genetic modification of NHP
and human ES cells remains challenging. Gene transfer in
primate ES cells is relatively inefficient compared to that
of mouse ES cells using conventional methods such as
lipofectamine or electroporation. This could be due to the
suboptimal culture condition and difficulty in single cell
culture. Although success in transfecting NHP and human
ES cells has been reported, gene transfer efficiency
remains low and challenging for complex gene modifica-
tion such as rare homologous recombination events
[68,69]. Not until recently, has development of the lenti-
viral vector significantly improved gene transfer efficiency
in cell types such as neurons with low mitotic rates or
which are non-proliferative [70,71]. As a result, NHP and
human ES cells expressing a green fluorescent protein
gene (GFP) were established [72]. Development of the
lentiviral vector, greatly improving gene transfer efficiency
in NHP and human ES cells, is an important step in the
development of gene and cell therapy using in vitro
derived cell types. Nonetheless, one of the major limita-
tions of RV and LV is the random integration event that
allows only overexpression of the gene of interest. An
alternative strategy is the application of RNA interference
(RNAi) technology to achieve gene targeted knock-down
of a specific gene product. By introducing a homologous
dsRNA to the specifically targeted gene product, a null or
hypomorphic phenotype resulted from the loss of the tar-
geted endogenous mRNA [73,74]. Additionally, recently
reported gene targeting by homologous recombination in
the human ES cell has led to a new era of human ES cell
application [69]. However, targeting efficiency remains
low and limited to simple gene manipulation. Thus, alter-
native approaches such as RNAi and a tetracycline-regu-
lated gene expression system should be considered [71].
Furthermore, due to the ethical limitations of human ES
cells, some procedures such as cell transplantation are
allowed to be performed in patients only at the end stage.
Development and validation of the efficacy of medical
intervention and cures is difficult without an appropriate
animal model. Thus, an animal model such as NHP is
important for the advancement of developing cures and
preventive medication. However, genetic disorders are
caused not only by single dominant gene defects, but also
by recessive and multiple gene defects. Therefore, it will
not be possible to generate an animal model by simply
over expressing the mutant gene; it will be necessary to
replace both endogenous alleles. Thus, gene targeting by
RNAi or homologous recombination in ES cells followed
by NT are the only alternatives in developing genetically
modified NHP models for recessive gene disorders.
Although tremendous effort has been expended to clone
NHPs using ES cells or somatic cells, no success has been
reported [51,75]. Nonetheless, efforts will continue to
develop cloning techniques in the NHP because of the
foreseeable impact of NHP models with identical genes
targeted in biomedical research – the creation of a herd of
identical animals carrying a unique genotype and poten-
tially an identical phenotype for pharmaceuticals, thera-
peutics and vaccine testing [21,76-79]; for the production
of valuable proteins [80,81], and for the study of cell dif-
ferentiation and potential applications of therapeutic
cloning [82-88]. Although many applications of NT can
be easily linked to NHP models, and the profound impact
of stem cell research and gene targeted mice has been
clearly demonstrated [6,88-93], the technical barriers for
NT in the NHP hss not yet been overcome. To date, no
cloned NHP has been produced using embryonic stem
cells or somatic cells as the donor nucleus. There have
been reports of low efficiency, high fetal loss, and defi-
ciency in immune, respiratory and other systems in new-
borns resulting from NT using somatic nuclei in many
species [94]. Criticism has been raised on current cloning
methods in the NHP and further investigation should be
performed before conclusive comments can be made.
Other techniques such as NT using blastomeres from pre-
implantation embryos [51] and embryo splitting [21]
have also been suggested as an alternative strategy to pro-
duce identical NHPs for immediate needs. However, the
number of blastomeres is the major limitation and the
production of gene targeted identical individuals is not
feasible [21,95].
In addition to production of an identical NHP model, in
vitro differentiation of ES cells is a potential source for
replacement therapy in cellular degenerative diseases like
AP, PD and HD. Cell types such as neurons, cardiac mus-
cle and islets, have been successfully generated from ES
cells in vitro under stringent culture conditions [65,67,88].
However, high purity ES cell derived cell types must be
achieved before cell transplantation can proceed, undif-
ferentiate ES cells are potentially neoplastic. Additional
concerns include the function of the derived cell types,
and potential immuno-rejection must be determined
before any clinical application. Thus, a transgenic NHP
model will be crucial for determining the neoplasticity,Reproductive Biology and Endocrinology 2004, 2 http://www.rbej.com/content/2/1/39
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function and immuno-rejection of the derived cell types
following transplantation.
Prospect
Animal models play an important role in biomedical
advancement. Appropriate use and design of an animal
model that mimics physiologic and pathologic conditions
in humans is the determining factor for advancing our
knowledge. Undoubtedly, rodents are critical for the
understanding of diseases and the development of cures
but they are not without limitations. Although no single
animal model perfectly mimics human diseases, compar-
ative studies among a variety of animal models will
broaden our view from several perspectives. Clearly,
because of their high genetic and physiologic similarity to
humans, NHPs are considered among the best models for
humans, yet they can't be used in all cases. Rodents and
livestock are superior to NHPs in availability, handling
and cost. Therefore, NHPs should only be considered
when others are inadequate in mimicking such human
conditions as the lack of true neurodegeneration. Progress
in gene and cell therapy, the advancement of stem cell
technology and the need for efficacious and reliable vac-
cines have driven the development of NHP models that
are not only similar in physiology, but also carry similar
genetic defects that lead to diseases such as AD, PD and
HD. Therefore, the need of NHP models in complex dis-
eases such as neurodegenerative disorders is foreseeable
due to the lack of true representation in rodents. Trans-
genic and gene targeted NHPs are important for the devel-
opment of cures; our goal was well described by
Brooksbank [96]: "We hope disease models will not only be
of educational value but will also stimulate the use and
development of models that are truly relevant to human
disease, which will eventually catalyse the development of
safe and efficacious therapeutics for human use."
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